Bailard’s Harte-Hanks HHS Stock Holding History

Bailard’s Portfolio HHS Stock Details HHS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-11,716	Closed	-$137K	–	750
2022 Q4	$137K	Buy	+11,716	New	+$130K	0.01%	675

Other funds holding HHS

WCM

Westerly Capital Management San Francisco, California $368M AUM 42.67% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HIM

Hillsdale Investment Management Toronto, Ontario, Canada $3.68B AUM 62.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Krilogy Financial St. Louis, Missouri $3.11B AUM 20.67% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Bailard's HHS Position: Q1 2023 in Review

Bailard sold out of Harte-Hanks (HHS) in Q1 2023, closing a stake of 11,716 shares — an estimated $137K sold.

Bailard first reported a position in HHS in Q4 2022 and held it in 1 quarter. The position peaked at $137K in Q4 2022. 31 funds tracked by Wall St. Rank hold HHS as of Q1 2023.

Bailard reported no remaining Harte-Hanks position as of Q1 2023 after selling out during the quarter.
Bailard sold 11,716 Harte-Hanks shares in Q1 2023, an estimated $137K.
Bailard first reported a position in Harte-Hanks in Q4 2022 and held it in 1 quarter.
Bailard's Harte-Hanks position peaked at $137K in Q4 2022.
31 funds tracked by Wall St. Rank held Harte-Hanks as of Q1 2023.

Based on Bailard's 13F filing for Q1 2023, filed 8 May 2023.